{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:44:44Z","timestamp":1792611884803,"version":"4.5.0"},"reference-count":63,"publisher":"MyJove Corporation","issue":"188","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/63696","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T12:16:17Z","timestamp":1668168977000},"source":"Crossref","is-referenced-by-count":2,"title":["Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice"],"prefix":"10.3791","author":[{"given":"Wenli","family":"Mu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjie","family":"Zhen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayra A.","family":"Carrillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Rezek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Lizarraga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Kitchen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"issue":"9635","key":"ref1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(08)61113-7","type":"journal-article","article-title":"Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies","volume":"372","year":"2008","unstructured":"Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 372 (9635), 293-299 (2008).","journal-title":"Lancet"},{"issue":"8","key":"ref2","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1097\/QAD.0000000000000243","type":"journal-article","article-title":"Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy","volume":"28","author":"May","year":"2014","unstructured":"May, M. T. et al. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS. 28 (8), 1193-1202 (2014).","journal-title":"AIDS"},{"issue":"5322","key":"ref3","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1126\/science.277.5322.112","type":"journal-article","article-title":"Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease","volume":"277","author":"Autran","year":"1997","unstructured":"Autran, B. et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 277 (5322), 112-116 (1997).","journal-title":"Science"},{"issue":"13","key":"ref4","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","type":"journal-article","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators","volume":"338","author":"Palella","year":"1998","unstructured":"Palella Jr., F. J. et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. The New England Journal of Medcine. 338 (13), 853-860 (1998).","journal-title":"The New England Journal of Medicine"},{"issue":"5341","key":"ref5","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","type":"journal-article","article-title":"Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy","volume":"278","author":"Finzi","year":"1997","unstructured":"Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 278 (5341), 1295-1300 (1997).","journal-title":"Science"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/COH.0000000000000122","type":"journal-article","article-title":"How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs","volume":"10","author":"Ananworanich","year":"2015","unstructured":"Ananworanich, J., Dube, K., Chomont, N. How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs? Current Opinion in HIV and AIDS. 10 (1), 18-28 (2015).","journal-title":"Current Opinion in HIV and AIDS"},{"issue":"7512","key":"ref7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/nature13594","type":"journal-article","article-title":"Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys","volume":"512","author":"Whitney","year":"2014","unstructured":"Whitney, J. B. et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature. 512 (7512), 74-77 (2014).","journal-title":"Nature"},{"issue":"6","key":"ref8","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nm880","type":"journal-article","article-title":"Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4 T cells","volume":"9","author":"Siliciano","year":"2003","unstructured":"Siliciano, J. D. et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nature Medicine. 9 (6), 727-728 (2003).","journal-title":"Nature Medicine"},{"issue":"6","key":"ref9","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/ni.3152","type":"journal-article","article-title":"HIV reservoirs as obstacles and opportunities for an HIV cure","volume":"16","author":"Chun","year":"2015","unstructured":"Chun, T. W., Moir, S., Fauci, A. S. HIV reservoirs as obstacles and opportunities for an HIV cure. Nature Immunology. 16 (6), 584-589 (2015).","journal-title":"Nature Immunology"},{"issue":"8","key":"ref10","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/infdis\/jiu258","type":"journal-article","article-title":"Frailty in people aging with human immunodeficiency virus (HIV) infection","volume":"210","author":"Brothers","year":"2014","unstructured":"Brothers, T. D. et al. Frailty in people aging with human immunodeficiency virus (HIV) infection. Journal of Infectious Disease. 210 (8), 1170-1179 (2014).","journal-title":"Journal of Infectious Disease"},{"issue":"9622","key":"ref11","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","type":"journal-article","article-title":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration","volume":"371","year":"2008","unstructured":"D. A. D. Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 371 (9622), 1417-1426 (2008).","journal-title":"Lancet"},{"issue":"12","key":"ref12","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/cid\/ciu701","type":"journal-article","article-title":"Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study","volume":"59","author":"Schouten","year":"2014","unstructured":"Schouten, J. et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clinical Infectious Diseases. 59 (12), 1787-1797 (2014).","journal-title":"Clinical Infectious Diseases"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fimmu.2016.00012","type":"journal-article","article-title":"Animal models for HIV cure research","volume":"7","author":"Policicchio","year":"2016","unstructured":"Policicchio, B. B., Pandrea, I., Apetrei, C. Animal models for HIV cure research. Frontiers in Immunology. 7, 12 (2016).","journal-title":"Frontiers in Immunology"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/COH.0000000000000152","type":"journal-article","article-title":"Animal models in HIV-1 protection and therapy","volume":"10","author":"Hessell","year":"2015","unstructured":"Hessell, A. J., Haigwood, N. L. Animal models in HIV-1 protection and therapy. Current Opinion in HIV and AIDS. 10 (3), 170-176, (2015).","journal-title":"Current Opinion in HIV and AIDS"},{"issue":"8","key":"ref15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.tibtech.2007.05.004","type":"journal-article","article-title":"HIV\/AIDS: in search of an animal model","volume":"25","author":"Ambrose","year":"2007","unstructured":"Ambrose, Z., KewalRamani, V. N., Bieniasz, P. D.. Hatziioannou, T. HIV\/AIDS: in search of an animal model. Trends in Biotechnology. 25 (8), 333-337 (2007).","journal-title":"Trends in Biotechnology"},{"issue":"11","key":"ref16","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/nm1431","type":"journal-article","article-title":"Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1","volume":"12","author":"Melkus","year":"2006","unstructured":"Melkus, M. W. et al. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nature Medicine. 12 (11), 1316--1322 (2006).","journal-title":"Nature Medicine"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1182\/blood-2005-11-4388","type":"journal-article","article-title":"Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus\/liver and CD34+ cell transplantation","volume":"108","author":"Lan","year":"2006","unstructured":"Lan, P., Tonomura, N., Shimizu, A., Wang, S., Yang, Y. G. Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus\/liver and CD34+ cell transplantation. Blood. 108 (2), 487-492 (2006).","journal-title":"Blood"},{"key":"ref18","first-page":"149","type":"journal-article","article-title":"Functional and phenotypic characterization of the humanized BLT mouse model","volume":"324","author":"Wege","year":"2008","unstructured":"Wege, A. K., Melkus, M. W., Denton, P. W., Estes, J. D., Garcia, J. V. Functional and phenotypic characterization of the humanized BLT mouse model. Current Topics in Microbiology and Immunology. 324, 149-165 (2008).","journal-title":"Current Topics in Microbiology and Immunology"},{"issue":"2","key":"ref19","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1172\/JCI80562","type":"journal-article","article-title":"In vivo platforms for analysis of HIV persistence and eradication","volume":"126","author":"Garcia","year":"2016","unstructured":"Garcia, J. V. In vivo platforms for analysis of HIV persistence and eradication. The Journal of Clinical Investigation. 126 (2), 424-431 (2016).","journal-title":"The Journal of Clinical Investigation"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3389\/fimmu.2018.00746","type":"journal-article","article-title":"The use of the humanized mouse model in gene therapy and immunotherapy for HIV and cancer","volume":"9","author":"Carrillo","year":"2018","unstructured":"Carrillo, M. A., Zhen, A., Kitchen, S. G. The use of the humanized mouse model in gene therapy and immunotherapy for HIV and cancer. Frontiers in Immunology. 9, 746 (2018).","journal-title":"Frontiers in Immunology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"636775","DOI":"10.3389\/fimmu.2021.636775","type":"journal-article","article-title":"Humanized mice for the evaluation of novel HIV-1 therapies","volume":"12","author":"Abeynaike","year":"2021","unstructured":"Abeynaike, S., Paust, S. Humanized mice for the evaluation of novel HIV-1 therapies. Frontiers in Immunology. 12, 636775 (2021).","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1146\/annurev-virology-101416-041703","type":"journal-article","article-title":"Humanized mouse models for human immunodeficiency virus infection","volume":"4","author":"Marsden","year":"2017","unstructured":"Marsden, M. D., Zack, J. A. Humanized mouse models for human immunodeficiency virus infection. Annual Review of Virology. 4 (1), 393-412 (2017).","journal-title":"Annual Review of Virology"},{"issue":"14","key":"ref23","doi-asserted-by":"crossref","first-page":"7305","DOI":"10.1128\/JVI.02207-08","type":"journal-article","article-title":"Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice","volume":"83","author":"Brainard","year":"2009","unstructured":"Brainard, D. M. et al. Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. Journal of Virology. 83 (14), 7305-7321 (2009).","journal-title":"Journal of Virology"},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"38853","DOI":"10.1371\/journal.pone.0038853","type":"journal-article","article-title":"Humanized mice recapitulate key features of HIV-1 infection: a novel concept using long-acting anti-retroviral drugs for treating HIV-1","volume":"7","author":"Nischang","year":"2012","unstructured":"Nischang, M. et al. Humanized mice recapitulate key features of HIV-1 infection: a novel concept using long-acting anti-retroviral drugs for treating HIV-1. PLoS One. 7 (6), e38853 (2012).","journal-title":"PLoS One"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"667393","DOI":"10.3389\/fimmu.2021.667393","type":"journal-article","article-title":"Innate immune reconstitution in humanized bone marrow-liver-thymus (HuBLT) mice governs adaptive cellular immune function and responses to HIV-1 infection","volume":"12","author":"Garcia-Beltran","year":"2021","unstructured":"Garcia-Beltran, W. F. et al. Innate immune reconstitution in humanized bone marrow-liver-thymus (HuBLT) mice governs adaptive cellular immune function and responses to HIV-1 infection. Frontiers in Immunology. 12, 667393 (2021).","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1172\/JCI90745","type":"journal-article","article-title":"Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs","volume":"127","author":"Cheng","year":"2017","unstructured":"Cheng, L. et al. Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs. The Journal of Clinical Investigation. 127 (1), 269-279 (2017).","journal-title":"The Journal of Clinical Investigation"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1172\/JCI89488","type":"journal-article","article-title":"Targeting type I interferon-mediated activation restores immune function in chronic HIV infection","volume":"127","author":"Zhen","year":"2017","unstructured":"Zhen, A. et al. Targeting type I interferon-mediated activation restores immune function in chronic HIV infection. The Journal of Clinical Investigation. 127 (1), 260-268 (2017).","journal-title":"The Journal of Clinical Investigation"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.omtm.2017.11.008","type":"journal-article","article-title":"Modeling anti-HIV-1 HSPC-based gene therapy in humanized mice previously infected with HIV-1","volume":"9","author":"Khamaikawin","year":"2018","unstructured":"Khamaikawin, W. et al. Modeling anti-HIV-1 HSPC-based gene therapy in humanized mice previously infected with HIV-1. Molecular Therapy Methods & Clinical Development. 9, 23-32 (2018).","journal-title":"Molecular Therapy Methods & Clinical Development"},{"issue":"12","key":"ref29","doi-asserted-by":"crossref","first-page":"8208","DOI":"10.1371\/journal.pone.0008208","type":"journal-article","article-title":"Engineering antigen-specific T cells from genetically modified human hematopoietic stem cells in immunodeficient mice","volume":"4","author":"Kitchen","year":"2009","unstructured":"Kitchen, S. G. et al. Engineering antigen-specific T cells from genetically modified human hematopoietic stem cells in immunodeficient mice. PLoS One. 4 (12), e8208 (2009).","journal-title":"PLoS One"},{"issue":"4","key":"ref30","doi-asserted-by":"crossref","first-page":"1009404","DOI":"10.1371\/journal.ppat.1009404","type":"journal-article","article-title":"Robust CAR-T memory formation and function via hematopoietic stem cell delivery","volume":"17","author":"Zhen","year":"2021","unstructured":"Zhen, A. et al. Robust CAR-T memory formation and function via hematopoietic stem cell delivery. PLoS Pathogens. 17 (4), e1009404 (2021).","journal-title":"PLoS Pathogens"},{"issue":"8","key":"ref31","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/mt.2015.102","type":"journal-article","article-title":"HIV-specific immunity derived from chimeric antigen receptor-engineered stem cells","volume":"23","author":"Zhen","year":"2015","unstructured":"Zhen, A. et al. HIV-specific immunity derived from chimeric antigen receptor-engineered stem cells. Molecular Therapy. 23 (8), 1358-1367 (2015).","journal-title":"Molecular Therapy"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/v6010001","type":"journal-article","article-title":"Stem-cell-based gene therapy for HIV infection","volume":"6","author":"Zhen","year":"2013","unstructured":"Zhen, A., Kitchen, S. Stem-cell-based gene therapy for HIV infection. Viruses. 6 (1), 1-12 (2013).","journal-title":"Viruses"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3389\/fcimb.2020.00410","type":"journal-article","article-title":"Engineering CAR T cells to target the hiv reservoir","volume":"10","author":"Mu","year":"2020","unstructured":"Mu, W., Carrillo, M. A., Kitchen, S. G. Engineering CAR T cells to target the hiv reservoir. Frontiers in Celluar and Infection Microbiology. 10, 410 (2020).","journal-title":"Frontiers in Celluar and Infection Microbiology"},{"issue":"4","key":"ref34","doi-asserted-by":"crossref","first-page":"007161","DOI":"10.1101\/cshperspect.a007161","type":"journal-article","article-title":"HIV-1 antiretroviral drug therapy","volume":"2","author":"Arts","year":"2012","unstructured":"Arts, E. J., Hazuda, D. J. HIV-1 antiretroviral drug therapy. Cold Spring Harbour Perspectives in Medicine. 2 (4), a007161 (2012).","journal-title":"Cold Spring Harbour Perspectives in Medicine"},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1128\/JVI.06120-11","type":"journal-article","article-title":"Generation of HIV latency in humanized BLT mice","volume":"86","author":"Denton","year":"2012","unstructured":"Denton, P. W. et al. Generation of HIV latency in humanized BLT mice. Journal of Virology. 86 (1), 630-634 (2012).","journal-title":"Journal of Virology"},{"issue":"6","key":"ref36","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/jac\/dkw042","type":"journal-article","article-title":"A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges","volume":"71","author":"Kovarova","year":"2016","unstructured":"Kovarova, M. et al. A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges. Journal of Antimicrobial Chemotherapy. 71 (6), 1586-1596 (2016).","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"1","key":"ref37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAD.0000000000001674","type":"journal-article","article-title":"An advanced BLT-humanized mouse model for extended HIV-1 cure studies","volume":"32","author":"Lavender","year":"2018","unstructured":"Lavender, K. J. et al. An advanced BLT-humanized mouse model for extended HIV-1 cure studies. AIDS. 32 (1), 1-10 (2018).","journal-title":"AIDS"},{"issue":"1","key":"ref38","doi-asserted-by":"crossref","first-page":"1003872","DOI":"10.1371\/journal.ppat.1003872","type":"journal-article","article-title":"Targeted cytotoxic therapy kills persisting HIV infected cells during ART","volume":"10","author":"Denton","year":"2014","unstructured":"Denton, P. W. et al. Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathogens. 10 (1), e1003872 (2014).","journal-title":"PLoS Pathogens"},{"issue":"9","key":"ref39","doi-asserted-by":"crossref","first-page":"1006575","DOI":"10.1371\/journal.ppat.1006575","type":"journal-article","article-title":"In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication","volume":"13","author":"Marsden","year":"2017","unstructured":"Marsden, M. D. et al. In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell \"kick\" and \"kill\" in strategy for virus eradication. PLoS Pathogens. 13 (9), e1006575 (2017).","journal-title":"PLoS Pathogens"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"14288","DOI":"10.1038\/srep14288","type":"journal-article","article-title":"Reducing the stress of drug administration: implications for the 3Rs","volume":"5","author":"Stuart","year":"2015","unstructured":"Stuart, S. A., Robinson, E. S. Reducing the stress of drug administration: implications for the 3Rs. Science Report. 5, 14288 (2015).","journal-title":"Science Report"},{"issue":"5","key":"ref41","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.cell.2014.07.043","type":"journal-article","article-title":"Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice","volume":"158","author":"Halper-Stromberg","year":"2014","unstructured":"Halper-Stromberg, A. et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell. 158 (5), 989-999 (2014).","journal-title":"Cell"},{"issue":"1","key":"ref42","doi-asserted-by":"crossref","first-page":"1010160","DOI":"10.1371\/journal.ppat.1010160","type":"journal-article","article-title":"ApoA-I mimetics reduce systemic and gut inflammation in chronic treated HIV","volume":"18","author":"Daskou","year":"2022","unstructured":"Daskou, M. et al. ApoA-I mimetics reduce systemic and gut inflammation in chronic treated HIV. PLoS Pathogens. 18 (1), e1010160 (2022).","journal-title":"PLoS Pathogens"},{"issue":"4","key":"ref43","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/QAD.0000000000002785","type":"journal-article","article-title":"Apolipoprotein A-I mimetics attenuate macrophage activation in chronic treated HIV","volume":"35","author":"Mu","year":"2021","unstructured":"Mu, W. et al. Apolipoprotein A-I mimetics attenuate macrophage activation in chronic treated HIV. AIDS. 35 (4), 543-553 (2021).","journal-title":"AIDS"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"154888","DOI":"10.1016\/j.metabol.2021.154888","type":"journal-article","article-title":"ApoA-I mimetics favorably impact cyclooxygenase 2 and bioactive lipids that may contribute to cardiometabolic syndrome in chronic treated HIV","volume":"124","author":"Daskou","year":"2021","unstructured":"Daskou, M. et al. ApoA-I mimetics favorably impact cyclooxygenase 2 and bioactive lipids that may contribute to cardiometabolic syndrome in chronic treated HIV. Metabolism. 124, 154888 (2021).","journal-title":"Metabolism"},{"issue":"7","key":"ref45","doi-asserted-by":"crossref","first-page":"02118","DOI":"10.1128\/JVI.02118-17","type":"journal-article","article-title":"HIV replication and latency in a humanized NSG mouse model during suppressive oral combinational antiretroviral therapy","volume":"92","author":"Satheesan","year":"2018","unstructured":"Satheesan, S. et al. HIV replication and latency in a humanized NSG mouse model during suppressive oral combinational antiretroviral therapy. Journal of Virology. 92 (7), e02118-17, (2018).","journal-title":"Journal of Virology"},{"issue":"10","key":"ref46","doi-asserted-by":"crossref","first-page":"02086","DOI":"10.1128\/JVI.02086-18","type":"journal-article","article-title":"Humanized mouse model of HIV-1 latency with enrichment of latent virus in PD-1(+) and TIGIT(+) CD4 T cells","volume":"93","author":"Llewellyn","year":"2019","unstructured":"Llewellyn, G. N. et al. Humanized mouse model of HIV-1 latency with enrichment of latent virus in PD-1(+) and TIGIT(+) CD4 T cells. Journal of Virology. 93 (10), e02086-18 (2019).","journal-title":"Journal of Virology"},{"issue":"9","key":"ref47","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2165\/00003088-200443090-00003","type":"journal-article","article-title":"Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics","volume":"43","author":"Kearney","year":"2004","unstructured":"Kearney, B. P., Flaherty, J. F., Shah, J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clinical Pharmacokinetics. 43 (9), 595-612 (2004).","journal-title":"Clinical Pharmacokinetics"},{"issue":"8","key":"ref48","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/s41366-019-0363-7","type":"journal-article","article-title":"Use of high-fat diets to study rodent obesity as a model of human obesity","volume":"43","author":"Speakman","year":"2019","unstructured":"Speakman, J. R. Use of high-fat diets to study rodent obesity as a model of human obesity. International Journal of Obesity (Lond). 43 (8), 1491-1492 (2019).","journal-title":"International Journal of Obesity (Lond)"},{"issue":"113","key":"ref49","first-page":"e54048","type":"journal-article","article-title":"Stem-cell based engineered immunity against HIV infection in the humanized mouse model","author":"Zhen","year":"2016","unstructured":"Zhen, A. et al. Stem-cell based engineered immunity against HIV infection in the humanized mouse model. Journal of Visualized Experiments. 113, 10.3791\/54048 (2016).","journal-title":"Journal of Visualized Experiments"},{"issue":"116","key":"ref50","first-page":"e54270","type":"journal-article","article-title":"A detailed protocol for characterizing the murine C1498 cell line and its associated leukemia mouse model","author":"Mopin","year":"2016","unstructured":"Mopin, A., Driss, V., Brinster, C. A detailed protocol for characterizing the murine C1498 cell line and its associated leukemia mouse model. Journal of Visualized Experiments. 116, 10.3791\/54270 (2016).","journal-title":"Journal of Visualized Experiments"},{"issue":"1","key":"ref51","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/laban0108-26","type":"journal-article","article-title":"Comparison of the lateral tail vein and the retro-orbital venous sinus as routes of intravenous drug delivery in a transgenic mouse model","volume":"37","author":"Steel","year":"2008","unstructured":"Steel, C. D., Stephens, A. L., Hahto, S. M., Singletary, S. J., Ciavarra, R. P. Comparison of the lateral tail vein and the retro-orbital venous sinus as routes of intravenous drug delivery in a transgenic mouse model. Lab Animal (NY). 37 (1), 26-32 (2008).","journal-title":"Lab Animal (NY)"},{"issue":"5","key":"ref52","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/laban0511-155","type":"journal-article","article-title":"Retro-orbital injections in mice","volume":"40","author":"Yardeni","year":"2011","unstructured":"Yardeni, T., Eckhaus, M., Morris, H. D., Huizing, M., Hoogstraten-Miller, S. Retro-orbital injections in mice. Lab Animal (NY). 40 (5), 155-160 (2011).","journal-title":"Lab Animal (NY)"},{"issue":"8","key":"ref53","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2009-04-215855","type":"journal-article","article-title":"A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model","volume":"115","author":"Shimizu","year":"2010","unstructured":"Shimizu, S. et al. A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood. 115 (8), 1534-1544 (2010).","journal-title":"Blood"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"46916","DOI":"10.7554\/eLife.46916","type":"journal-article","article-title":"Mechanisms of virus dissemination in bone marrow of HIV-1-infected humanized BLT mice","volume":"8","author":"Ladinsky","year":"2019","unstructured":"Ladinsky, M. S. et al. Mechanisms of virus dissemination in bone marrow of HIV-1-infected humanized BLT mice. Elife. 8, e46916 (2019).","journal-title":"Elife"},{"issue":"5","key":"ref55","first-page":"600","type":"journal-article","article-title":"Administration of substances to laboratory animals: routes of administration and factors to consider","volume":"50","author":"Turner","year":"2011","unstructured":"Turner, P. V., Brabb, T., Pekow, C., Vasbinder, M. A. Administration of substances to laboratory animals: routes of administration and factors to consider. Journal of the American Association for Laboratory Animal Science. 50 (5), 600-613 (2011).","journal-title":"Journal of the American Association for Laboratory Animal Science"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"105980","DOI":"10.1155\/2012\/105980","type":"journal-article","article-title":"Effect of food on the steady-state pharmacokinetics of tenofovir and emtricitabine plus efavirenz in Ugandan adults","volume":"2012","author":"Lamorde","year":"2012","unstructured":"Lamorde, M. et al. Effect of food on the steady-state pharmacokinetics of tenofovir and emtricitabine plus efavirenz in Ugandan adults. AIDS Research and Treatment. 2012, 105980 (2012).","journal-title":"AIDS Research and Treatment"},{"issue":"3","key":"ref57","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.xphs.2016.12.003","type":"journal-article","article-title":"Development of a novel formulation that improves preclinical bioavailability of tenofovir disoproxil fumarate","volume":"106","author":"Watkins","year":"2017","unstructured":"Watkins, M. E. et al. Development of a novel formulation that improves preclinical bioavailability of tenofovir disoproxil fumarate. Journal of Pharmaceutical Sciences. 106 (3), 906-919 (2017).","journal-title":"Journal of Pharmaceutical Sciences"},{"issue":"3","key":"ref58","first-page":"323","type":"journal-article","article-title":"Evaluation of hydration and nutritional gels as supportive care after total-body irradiation in mice (Mus musculus)","volume":"49","author":"Moccia","year":"2010","unstructured":"Moccia, K. D., Olsen, C. H., Mitchell, J. M., Landauer, M. R. Evaluation of hydration and nutritional gels as supportive care after total-body irradiation in mice (Mus musculus). Journal of the American Association for Laboratory Animal Science. 49 (3), 323-328 (2010).","journal-title":"Journal of the American Association for Laboratory Animal Science"},{"issue":"2","key":"ref59","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","type":"journal-article","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","unstructured":"Nair, A. B., Jacob, S. A simple practice guide for dose conversion between animals and human. Journal of Basic and Clinical Pharmacy. 7 (2), 27-31 (2016).","journal-title":"Journal of Basic and Clinical Pharmacy"},{"issue":"7","key":"ref60","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0006-2952(03)00002-9","type":"journal-article","article-title":"Multidisciplinary utilization of dimethyl sulfoxide: pharmacological, cellular, and molecular aspects","volume":"65","author":"Santos","year":"2003","unstructured":"Santos, N. C., Figueira-Coelho, J., Martins-Silva, J., Saldanha, C. Multidisciplinary utilization of dimethyl sulfoxide: pharmacological, cellular, and molecular aspects. Biochemical Pharmacology. 65 (7), 1035-1041 (2003).","journal-title":"Biochemical Pharmacology"},{"issue":"1","key":"ref61","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1749-6632.1967.tb34869.x","type":"journal-article","article-title":"Absorption, distribution and elimination of labeled dimethyl sulfoxide in man and animals","volume":"141","author":"Kolb","year":"1967","unstructured":"Kolb, K. H., Jaenicke, G., Kramer, M., Schulze, P. E. Absorption, distribution and elimination of labeled dimethyl sulfoxide in man and animals. Annals of the New York Academy of Sciences. 141 (1), 85-95 (1967).","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"8202","key":"ref62","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0140-6736(80)92158-3","type":"journal-article","article-title":"Dimethylsulphoxide-incuded toxicity","volume":"2","author":"Yellowlees","year":"1980","unstructured":"Yellowlees, P., Greenfield, C., McIntyre, N. Dimethylsulphoxide-induced toxicity. Lancet. 2 (8202), 1004-1006 (1980).","journal-title":"Lancet"},{"issue":"1-2","key":"ref63","first-page":"1","type":"journal-article","article-title":"Medical use of dimethyl sulfoxide (DMSO)","volume":"5","author":"Swanson","year":"1985","unstructured":"Swanson, B. N. Medical use of dimethyl sulfoxide (DMSO). Reviews in Clinical & Basic Pharmacology. 5 (1-2), 1-33 (1985).","journal-title":"Reviews in Clinical & Basic Pharmacology"}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jove.com\/t\/63696\/oral-combinational-antiretroviral-treatment-hiv-1-infected-humanized","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:16:34Z","timestamp":1792610194000},"score":1,"resource":{"primary":{"URL":"https:\/\/app.jove.com\/t\/63696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":63,"journal-issue":{"issue":"188","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.3791\/63696","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,6]]}}}